Zobrazeno 1 - 10
of 1 389
pro vyhledávání: ''
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Amy Kantor, Charles Flexner, Christina Gavegnano, Michael M. Lederman, Selwyn J. Hurwitz, Sijia Tao, Edgar T. Overton, Vincent C. Marconi, Raymond F. Schinazi, Randall Tressler, James J. Kohler, Carlos del Rio, Carlee Moser, Athe M. N. Tsibris, Yong Jiang, Jeffrey L. Lennox
Publikováno v:
J Clin Pharmacol
Ruxolitinib is an FDA-approved orally administered Janus kinase (JAK 1/2) inhibitor that reduces cytokine-induced inflammation. As part of a randomized, Phase 2, open label trial, ruxolitinib (10 mg, bid) was administered to HIV(+), virologically sup
Autor:
Cathrin Sauer, Hannelore Findeis, James Rucker, Michael Bauer, Allan H. Young, Philipp Ritter, Vera M Ludwig
Publikováno v:
CNS Drugs
Background (Es)ketamine and monoamine oxidase inhibitors (MAOIs), e.g., tranylcypromine, are therapeutic options for treatment-resistant major depression. Simultaneous administration is currently not recommended because of concern about hypertensive
Autor:
Dermot F. McGinnity, Diansong Zhou, Shringi Sharma, Buyun Chen, Venkatesh Pilla Reddy, Karthick Vishwanathan, Adrian J. Fretland, Joseph Ware, Yan Xu
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy
Autor:
Barkate Hanmant, Robert Dobbins, Susan Andrews, Bentley Cheatham, Robin O'Connor-Semmes, Elizabeth Hussey, Katare Sagar, Wenli Tao, William O. Wilkison
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-11 (2021)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
Background Patients with type 2 diabetes mellitus (T2DM) are characterized by an elevated glycemic index and are at a higher risk for complications such as cardiovascular disease, nephropathy, retinopathy and peripheral neuropathy. Normalization of g
Publikováno v:
Clinical Pharmacology in Drug Development
This pharmacokinetic (PK) drug‐interaction trial investigated the effects of repeated dosing of a plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral
Autor:
Amais Ahmad, Amin Rostami-Hodjegan, Annett Kunze, Frank Jacobs, Jan Snoeys, Kayode Ogungbenro, Aleksandra Galetin
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 467-477 (2021)
Ahmad, A, Ogungbenro, K, Kunze, A, Jacobs, F, Snoeys, J, Rostami-hodjegan, A & Galetin, A 2021, ' Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters ', CPT: Pharmacometrics and Systems Pharmacology, vol. 10, no. 5, pp. 467-477 . https://doi.org/10.1002/psp4.12610
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 467-477 (2021)
Ahmad, A, Ogungbenro, K, Kunze, A, Jacobs, F, Snoeys, J, Rostami-hodjegan, A & Galetin, A 2021, ' Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters ', CPT: Pharmacometrics and Systems Pharmacology, vol. 10, no. 5, pp. 467-477 . https://doi.org/10.1002/psp4.12610
Renal clearance of many drugs is mediated by renal organic anion transporters OAT1/3 and inhibition of these transporters may lead to drug‐drug interactions (DDIs). Pyridoxic acid (PDA) and homovanillic acid (HVA) were indicated as potential biomar
Publikováno v:
Clinical Pharmacology in Drug Development
GLPG1205 is a novel agent being investigated for the treatment of idiopathic pulmonary fibrosis. GLPG1205 may be concomitantly administered with pirfenidone in future clinical development; therefore, the potential for GLPG1205 to interact with enzyme
Publikováno v:
Clinical Pharmacology and Therapeutics
Bictegravir is equally metabolized by cytochrome P450 (CYP)3A and uridine diphosphate‐glucuronosyltransferase (UGT)1A1. Drug–drug interaction (DDI) studies were only conducted for strong inhibitors and inducers, leading to some uncertainty whethe
Autor:
Kazuoki Kondo, Yukiko Nishimura, Yuichiro Kato, Yoshinobu Nakamaru, Hidetoshi Shimizu, Hideaki Matsuda, Yoichi Shiide, Makoto Akimoto, Munetomo Matsuda
Publikováno v:
Clinical Pharmacology in Drug Development
Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formu